Lexaria Bioscience forms Scientific Advisory Board

Lexaria Bioscience (LEXX) announces the creation of its new Scientific Advisory Board to assist in guiding Lexaria’s rapid drug delivery platform technology and strategic development plans within the pharmaceutical industry. The SAB will initially be comprised of four people and the Chairman of the SAB will be Lexaria’s President and CEO, John Docherty. Mr. Docherty joined Lexaria in 2015, at the time of its earliest foundational work in the drug delivery technology arena and has led the Company’s scientific and intellectual property development programs since that time. Michael Gibson was recently announced by Lexaria as its new Chief Medical Advisor and will also participate on the SAB. Karen Aust has, among other roles, served as a Director of Regulatory Strategy and is currently a Senior Director of Regulatory Affairs at G&L Healthcare Advisors. Phil Ainslie is a Professor, Research Chair and co-directs the Centre of Heart, Lung and Vascular Health at the University of British Columbia, Canada.